Background

Age-related decline of HAS2 shifts hyaluronan synthesis from protective high‑molecular‑weight HA (HMW‑HA) to pro‑inflammatory low‑molecular‑weight fragments (LMW‑HA) [1,2,3]. LMW‑HA engages CD44, TLR2/4 and RHAMM, triggering sterile inflammation and, in chondrocytes and dermal fibroblasts, activates RhoA/ROCK signaling that drives cytoskeletal collapse, apoptosis or senescence [[1],[2],[3]]. Notably, CD44 can undergo ectodomain shedding, releasing an intracellular domain (CD44‑ICD) that translocates to the nucleus and influences gene expression [4]. Whether this nuclear pool directly represses HAS2 transcription remains unexplored.

Hypothesis

We propose that LMW‑HA–induced CD44 cleavage generates a nuclear CD44‑ICD that recruits histone deacetylases (HDAC1/2) to the HAS2 promoter, causing local chromatin condensation and transcriptional silencing. This creates a feed‑forward loop: reduced HAS2 diminishes HMW‑HA synthesis, elevating LMW‑HA levels, which further amplifies CD44‑ICD production and HAS2 repression.

Predictions

• Prediction 1: LMW‑HA treatment increases nuclear CD44‑ICD levels in chondrocytes and dermal fibroblasts.
• Prediction 2: Nuclear CD44‑ICD physically associates with HDAC1/2 at the HAS2 promoter, reducing histone H3 acetylation and HAS2 mRNA.
• Prediction 3: Pharmacological inhibition of HDACs or expression of a CD44 mutant incapable of nuclear translocation rescues HAS2 expression and HMW‑HA synthesis despite LMW‑HA exposure.
• Prediction 4: Disrupting the CD44‑ICD/HDAC interaction breaks the self‑amplifying loop, lowering inflammatory markers (e.g., IL‑6, COX‑2) and attenuating senescence or apoptosis phenotypes.

Experimental Approach

1. Cell culture: Primary human chondrocytes and dermal fibroblasts stimulated with defined LMW‑HA (≈200‑500 kDa) for 24 h.
2. Subcellular fractionation: Western blot for CD44‑ICD in nuclear vs cytoplasmic fractions; immunofluorescence to confirm nuclear localisation.
3. Chromatin immunoprecipitation (ChIP): Antibodies against CD44‑ICD, HDAC1/2, and acetyl‑H3K9 at the HAS2 promoter region; qPCR to quantify enrichment.
4. HDAC inhibition: Treat cells with trichostatin A (TSA) or selective HDAC1/2 inhibitors alongside LMW‑HA; measure HAS2 mRNA (RT‑qPCR) and secreted HA size distribution (ELISA‑based HA assay).
5. Mutant CD44: Overexpress a CD44 construct lacking the intracellular domain (ΔICD) or a nuclear‑export‑seq‑deficient mutant; assess whether LMW‑HA‑mediated HAS2 repression is blocked.
6. Phenotypic readouts: Senescence (SA‑β‑gal, p27), apoptosis (caspase‑3 cleavage), and inflammatory cytokines (IL‑6, IL‑1β) under each condition.

Potential Outcomes and Interpretation

• If LMW‑HA elevates nuclear CD44‑ICD, which co‑occupies the HAS2 promoter with HDACs and reduces promoter acetylation, the hypothesis is supported.
• Rescue of HAS2 expression and HMW‑HA synthesis by HDAC inhibition or ΔICD CD44 would confirm causality.
• Attenuation of senescence/apoptosis and inflammatory signaling upon disruption of the CD44‑ICD/HDAC axis would demonstrate the pathophysiological relevance of the proposed loop.
• Conversely, absence of CD44‑ICD nuclear accumulation or lack of HDAC recruitment would falsify the hypothesis, directing attention to alternative mechanisms (e.g., epigenetic modifiers activated downstream of RhoA/ROCK).

This mechanistic insight explains how an initial decline in HAS2 could become self‑propagating, offering a precise target—nuclear CD44‑ICD/HDAC interaction—to interrupt the vicious cycle of HA fragmentation, inflammation, and tissue degeneration in aging joints and skin.